NCT00056199View on ClinicalTrials.gov

EYE001 to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

March 31, 2003

Study Completion Date

November 30, 2005

Conditions
Hippel-Lindau Disease
Interventions
DRUG

EYE001

Trial Locations (1)

20892

National Eye Institute (NEI), Bethesda

All Listed Sponsors
lead

National Eye Institute (NEI)

NIH

NCT00056199 - EYE001 to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome | Biotech Hunter | Biotech Hunter